Wall Street analysts forecast that Abbott Laboratories (NYSE:ABT) will post earnings of $0.73 per share for the current quarter, according to Zacks Investment Research. Six analysts have provided estimates for Abbott Laboratories’ earnings. The lowest EPS estimate is $0.71 and the highest is $0.74. Abbott Laboratories posted earnings of $0.65 per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 12.3%. The business is expected to issue its next quarterly earnings report before the market opens on Wednesday, January 24th.

According to Zacks, analysts expect that Abbott Laboratories will report full-year earnings of $2.50 per share for the current year, with EPS estimates ranging from $2.48 to $2.53. For the next financial year, analysts expect that the business will report earnings of $2.83 per share, with EPS estimates ranging from $2.80 to $2.87. Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that cover Abbott Laboratories.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.01. The business had revenue of $6.83 billion during the quarter, compared to the consensus estimate of $6.72 billion. Abbott Laboratories had a net margin of 8.37% and a return on equity of 13.98%. The firm’s quarterly revenue was up 28.8% compared to the same quarter last year. During the same quarter last year, the firm earned $0.59 earnings per share.

ABT has been the subject of several analyst reports. ValuEngine downgraded shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Stifel Nicolaus raised their price objective on shares of Abbott Laboratories from $58.00 to $63.00 and gave the stock a “buy” rating in a research note on Thursday, October 19th. BMO Capital Markets reissued a “market perform” rating on shares of Abbott Laboratories in a research note on Thursday, October 19th. Zacks Investment Research raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $61.00 target price on the stock in a research report on Tuesday, October 31st. Finally, Royal Bank of Canada reaffirmed a “buy” rating and set a $55.00 target price on shares of Abbott Laboratories in a research report on Tuesday, October 3rd. Six investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $59.59.

Shares of Abbott Laboratories (ABT) traded up $0.17 during midday trading on Thursday, reaching $58.99. 5,771,367 shares of the company’s stock traded hands, compared to its average volume of 6,370,000. The company has a current ratio of 2.69, a quick ratio of 2.26 and a debt-to-equity ratio of 0.72. The company has a market capitalization of $102,680.00, a P/E ratio of 48.75, a P/E/G ratio of 1.88 and a beta of 1.55. Abbott Laboratories has a twelve month low of $39.25 and a twelve month high of $59.60.

The business also recently announced a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Friday, January 12th will be given a dividend of $0.28 per share. The ex-dividend date is Thursday, January 11th. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.27. This represents a $1.12 dividend on an annualized basis and a dividend yield of 1.90%. Abbott Laboratories’s dividend payout ratio (DPR) is 87.60%.

In related news, Chairman Miles D. White sold 276,886 shares of Abbott Laboratories stock in a transaction that occurred on Wednesday, December 6th. The shares were sold at an average price of $54.41, for a total transaction of $15,065,367.26. Following the transaction, the chairman now directly owns 3,677,913 shares of the company’s stock, valued at $200,115,246.33. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Daniel Gesua Sive Salvadori sold 28,319 shares of Abbott Laboratories stock in a transaction that occurred on Thursday, December 14th. The shares were sold at an average price of $54.92, for a total transaction of $1,555,279.48. Following the transaction, the insider now directly owns 102,117 shares in the company, valued at $5,608,265.64. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 501,172 shares of company stock worth $27,533,150. Corporate insiders own 0.76% of the company’s stock.

A number of hedge funds have recently modified their holdings of ABT. Heritage Trust Co increased its holdings in Abbott Laboratories by 10.1% during the second quarter. Heritage Trust Co now owns 2,175 shares of the healthcare product maker’s stock valued at $106,000 after buying an additional 200 shares during the period. Tributary Capital Management LLC purchased a new position in Abbott Laboratories during the third quarter valued at approximately $106,000. Winfield Associates Inc. increased its holdings in Abbott Laboratories by 3.9% during the second quarter. Winfield Associates Inc. now owns 2,382 shares of the healthcare product maker’s stock valued at $116,000 after buying an additional 89 shares during the period. Thompson Davis & CO. Inc. increased its holdings in Abbott Laboratories by 17.7% during the second quarter. Thompson Davis & CO. Inc. now owns 2,463 shares of the healthcare product maker’s stock valued at $120,000 after buying an additional 370 shares during the period. Finally, JFS Wealth Advisors LLC increased its holdings in Abbott Laboratories by 349.0% during the second quarter. JFS Wealth Advisors LLC now owns 2,694 shares of the healthcare product maker’s stock valued at $131,000 after buying an additional 2,094 shares during the period. 71.15% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This article was posted by Marea Informative and is the sole property of of Marea Informative. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.mareainformativa.com/2018/01/30/abbott-laboratories-abt-expected-to-announce-earnings-of-0-73-per-share-updated-updated-updated.html.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Get a free copy of the Zacks research report on Abbott Laboratories (ABT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.